• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us

POSTER: Enhancing Immunogenicity Risk Assessment: Leveraging ISPRI for Bispecific Antibody Analysis

by Elena Iemma | Apr 21, 2025

Immunogenicity of Generic Peptide Impurities: Current Orthogonal Approaches

by Elena Iemma | Mar 25, 2025

Poster: Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods

Poster: Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods

by Elena Iemma | May 23, 2024

Poster: An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)

Poster: An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)

by Elena Iemma | May 23, 2024

Poster: Prospectively Assessing the Immunogenic Risk of Potential Synthetic Peptide Impurities in silico with the What-if Machine (WhIM)

Poster: Prospectively Assessing the Immunogenic Risk of Potential Synthetic Peptide Impurities in silico with the What-if Machine (WhIM)

by Elena Iemma | Sep 21, 2023

Prospectively Assessing the Immunogenic Risk of Potential Synthetic Peptide Impurities in silico with the What-if Machine (WhIM)
« Older Entries

Recent Posts

  • Is “Artificial” Intelligence an Option for your ADA ?
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar: 2025
  • Tregs as Medicine: Tolerance and InTolerance Seminar
  • The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline